Video

The Potential Utility of CLR 131 in Multiple Myeloma

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Jarrod Longcor, MS, MBA, chief business officer, Cellectar Biosciences, Inc., discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

The primary objective of the phase I dose-escalation study (NCT02278315) is to determine the safety and tolerability of CLR 131 in patients with relapsed/refractory disease who have been previously treated with or are intolerant of an immunomodulatory drug and a proteasome inhibitor. Secondary objectives include identifying the recommended phase II dose and schedule and evaluating efficacy.

Patients will receive a fractionated infusion of CLR 131 at increasing doses on day 1 and 7 (±1 day) with concurrent weekly dexamethasone. Preclinical data demonstrated that CLR 131 inhibited tumor growth in mice.

Pending further study, CLR 131 could play a role in patients with triple-class refractory multiple myeloma who have received ≥5 prior lines of therapy, explains Longcor. Due to the design of the agent, the drug could potentially be used in combination with stem cell transplantation or as a bridge to CAR T-cell therapy, concludes Longcor.

Related Videos
Hope S. Rugo, MD
Idoroenyi Amanam, MD
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD
Domenica Lorusso, MD, PhD
Martin H. Voss, MD
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD